Bronchial aspiration of oropharyngeal content is the main risk factor for ventilator-associated pneumonia (VAP). Intermittent aspiration is a common strategy to decrease this content. Nevertheless, it requires direct action and can induce local complications. <b>Aim:</b> To evaluate the eficacy and safety of continuous supraglottic aspiration by using the SUPRAtube (a device of own innovation) in patients receiving mechanical ventilation. <b>Methods:</b> Randomized clinical trial where SUPRAtube is compared with conventional aspiration techniques. To date, 50 adult patients (56±19 years) have been included. The device was inserted in the first 12 hours and fixed at the supraglottic nadir (pressure, -20 cmH2O). Efficacy was assessed by quantifying the volume of the aspirate. Safety was evaluated by through two consecutive videoendoscopies. <b>Results:</b> In the control group, the aspiration volume was 25±6 ml/day. In the SUPRAtube group it was 269±48 ml/day (p&lt;0.001), with a weight/time ratio of 0.3±0.1 vs. 3±1 gr/h (p&lt;0.01). The SUPRAtube associated with greater resolution of bronchoscopic abnormalities (11 vs. 56%, p=0.04). Cultures of the bronchial secretions negativized in 88% of controls vs. 93% of SUPRAtube group (p=ns). The device did not induce local adverse events (erythema, edema, bruising, hemorrhage, clots, or any other non-expected damage). <b>Conclusions:</b> The continuous supraglottic aspiration using the new SUPRAtube device is a safe, simple and low cost technique able to avoid the accumulation of oropharyngeal secretions in mechanically ventilated patients. Supported by FCV and COLCIENCIAS, ref. 656677758334 (833-2017)